OmniAb (OABI) Non Operating Income (2022 - 2026)
OmniAb (OABI) posted quarterly Non Operating Income of $564000.0 for Q1 2026, up 4.83% year-over-year from $538000.0 in Q1 2025, and down 53.77% quarter-over-quarter from $1.2 million in Q4 2025.
OmniAb (OABI) Non Operating Income (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported Non Operating Income for 5 consecutive years, with $564000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 4.83% year-over-year to $564000.0; the TTM figure through Mar 2026 stood at $2.7 million (up 1.77% YoY), while the FY2025 annual figure was $2.7 million, down 13.46% from the prior year.
- Non Operating Income declined to $564000.0 in Q1 2026 per OABI's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.3 million in Q1 2023 and bottomed at $454000.0 in Q3 2025.
- Historically, Non Operating Income has averaged $855214.3 across 5 years, with a median of $729500.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 100.68% — and 2024, when it plunged 46.35%.
- OmniAb's Non Operating Income stood at $587000.0 in 2022, then soared by 100.68% to $1.2 million in 2023, then plunged by 44.23% to $657000.0 in 2024, then surged by 85.69% to $1.2 million in 2025, then sank by 53.77% to $564000.0 in 2026.
- Business Quant data shows OABI's Non Operating Income at $564000.0 in Q1 2026, $1.2 million in Q4 2025, and $454000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 425,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 425,000.00 |
| Mar 31, 2026 | 564,000.00 |
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 454,000.00 |
| Jun 30, 2025 | 463,000.00 |
| Mar 31, 2025 | 538,000.00 |
| Dec 31, 2024 | 657,000.00 |
| Sep 30, 2024 | 683,000.00 |
| Jun 30, 2024 | 776,000.00 |
| Mar 31, 2024 | 975,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 587,000.00 |